drugset / Trial / NCT05431764
Whole-target Consolidation Therapy Under Systemic Therapy for Oligometastatic Nasopharyngeal Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
In this exploratory clinical trial, patients with newly diagnosed distant metastatic nasopharyngeal carcinoma were treated with gemcitabine+ cisplatin+PD-1 inhibitor regimen followed by whole-target radiotherapy (IMRT for local regional lesion, SBRT for distant metastasis) and PD-1 inhibitor long-term maintenance regimen. To investigate the efficacy and safety of "whole target" radiotherapy combined with immuno-maintenance therapy.
Timeline
- Start
- 2022-06-20
- Primary completion
- 2025-06-20
- Completion
- 2026-06-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camrelizumab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | Cisplatin | Other / unclassified | 80 mg/m2 | — |
| Subject | Gemcitabine | Small molecule | 1000 mg/m2 | — |